Shift from Pre-Specified to Composite Endpoint

BioVie Inc. (BIVI) announced the results of its SUNRISE-PD Phase 2b clinical trial, which evaluated bezisterim (NE3107) as a monotherapy in patients with early Parkinson's disease. The trial involved 57 patients randomized 1:1 to receive either 20mg of bezisterim or a placebo twice daily for 12 weeks. Instead of prominently presenting the pre-registered primary endpoint, the change in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, the company emphasized the EPNIC-15, a composite of 15 motor and non-motor items, as the key evidence. This shift in focus, highlighting a new composite endpoint over the pre-specified scale, has made the reproducibility of the efficacy signal and its potential for regulatory use a central point of contention for investors.

Gap Between Statistical Significance and Clinical Persuasiveness

The change in EPNIC-15 score was -0.04 points in the bezisterim group and +0.18 points in the placebo group, with a statistically significant difference between the groups (p=0.0006). However, the interpretation of the results was more positive in the subgroup with a baseline platelet count of 230×10³/µL or higher, compared to the overall patient population. While platelets can be associated with inflammatory states, they are not an FDA-approved companion diagnostic or surrogate marker for selecting patients who will respond to Parkinson's disease treatment. Therefore, this signal needs to be replicated in a subsequent trial with pre-specified stratification based on platelet levels to support development decisions.

Differentiated Mechanism, Early Stage of Validation

Bezisterim, an oral investigational drug currently in development without a brand name, is designed to cross the blood-brain barrier and bind to ERK, thereby modulating NF-κB activation, TNF-α production, and insulin resistance. Unlike standard treatments that supplement dopamine, it strategically differentiates itself by targeting neuroinflammation, aiming to improve symptoms and slow disease progression. However, it is currently in Phase 2b, and has not yet entered Phase 3 trials, nor has it been submitted to the FDA, EMA, or PMDA for approval, or undergone review by an advisory committee (AdComm). In its August 2024 review of the SUNRISE-PD protocol, the FDA recommended including MDS-UPDRS Part II as a primary endpoint for future pivotal trials. Therefore, relying solely on a post-hoc composite endpoint makes it difficult to support the design of a Phase 3 trial.

Market and Competitive Landscape Demands Rigor

The global Parkinson's disease market was valued at $5.7 billion in 2024 and is projected to grow to $7.6 billion in 2030, but the majority of sales are still generated by carbidopa/levodopa-based therapies. Crexont (carbidopa/levodopa) from Amneal Pharmaceuticals (AMRX) was approved by the FDA on August 7, 2024, and Vyalev (foscarbidopa/foslevodopa) from AbbVie (ABBV) was approved on October 16, 2024. These are both commercially available competitors that aim to reduce motor fluctuations, with Vyalev being a sustained-release oral formulation and Crexont being a 24-hour subcutaneous infusion. In the pipeline for early Parkinson's disease, Roche (RHHBY) and Prothena (PRTA)'s anti-α-synuclein antibody, prasinezumab, also represent a competitive force. The approximately 50% drop in BioVie's stock price after the announcement reflects the market's assessment that, given the small sample size and post-hoc analysis, it will be difficult to secure funding and partnerships for a Phase 3 trial in this competitive environment.